Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03768531
Title Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Indications

biliary tract cancer

Therapies

Cabiralizumab + Nivolumab

Nivolumab

Age Groups: senior | adult
Covered Countries

Facility Status City State Zip Country Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field